A
Allison L. Marlow
Researcher at Anschutz Medical Campus
Publications - 32
Citations - 1693
Allison L. Marlow is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 11, co-authored 32 publications receiving 1642 citations.
Papers
More filters
Journal ArticleDOI
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
Alex A. Adjei,Roger B. Cohen,Wilbur A. Franklin,Clive Morris,David S. Wilson,Julian R. Molina,Lorelei J. Hanson,Lia Gore,Laura Q M Chow,Stephen Leong,Lara Maloney,Gilad Gordon,Heidi Simmons,Allison L. Marlow,Kevin Litwiler,Suzy Brown,Gregory Poch,Katie Kane,Jerry Haney,S. Gail Eckhardt +19 more
TL;DR: AZD6244 was well tolerated with target inhibition demonstrated at the recommended phase II dose and PK analyses supported twice-daily dosing, and prolonged SD was seen in a variety of advanced cancers.
Journal ArticleDOI
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
Tammie C. Yeh,Vivienne Marsh,Bryan Bernat,Josh Ballard,Heidi Colwell,Ronald Evans,Janet Parry,Darin Smith,Barbara J. Brandhuber,Stefan Gross,Allison L. Marlow,Hurley Brian T,Lyssikatos Joseph P,Patrice Lee,James D. Winkler,Kevin Koch,Eli M. Wallace +16 more
TL;DR: ARRY-142886 is a potent and selective MEK1/2 inhibitor that is highly active in both in vitro and in vivo tumor models.
Patent
N3 alkylated benzimidazole derivatives as MEK inhibitors
TL;DR: In this paper, compounds of the formula I, and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification.
Patent
Heterocyclic inhibitors of mek and methods of use thereof
Allison L. Marlow,Eli M. Wallace,Jeongbeob Seo,Joseph P. Lyssikatos,Hong Woon Yang,James F. Blake +5 more
TL;DR: In this article, the MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions, were discussed.
Patent
Quinoline compounds and methods of use
John Gaudino,Steven A. Boyd,Allison L. Marlow,Tomas Kaplan,Kin Chiu Fong,Jeongbeob Seo,Hongqi Tian,James F. Blake,Kevin Koch +8 more
TL;DR: In this paper, methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.